Effects of oral administration of insulin-like growth factor-I on circulating concentration of insulin-like growth factor-I and growth of internal organs in weanling mice

被引:7
|
作者
Kim, WK
Ryu, YH
Seo, DS
Lee, CY
Ko, Y [1 ]
机构
[1] Korea Univ, Coll Life & Environm Sci, Div Life Sci & Genet Engn, Seoul 136701, South Korea
[2] Jinju Natl Univ, Reg Anim Ind Res Ctr, Jinju, South Korea
来源
BIOLOGY OF THE NEONATE | 2006年 / 89卷 / 03期
关键词
insulin-like growth factor-1; oral administration; growth; organ; mouse;
D O I
10.1159/000089796
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Insulin-like growth factor (IGF)-I is a polypeptide that mediates the growth-promoting action of growth hormone in postnatal animals. The present study was conducted to examine whether orally administered IGF-I would be absorbed into the general circulation and also whether ingested IGF-I would enhance the growth of whole body as well as internal organs, and tissues in 3-week-old ICR-strain female weanling mice. In experiment (Exp) 1, a total of 70 mice received IGF-I orally at 1 mu g.g(-1) in 0.2-ml PBS or the vehicle alone. Concentrations of IGF-I and glucose in heart blood were measured after killing 5 animals in each group every fourth hour during a 24-hour period. In Exp 2, a total of 40 mice received oral IGF-I administration at 1 mu g.g(-1) or vehicle every third day beginning from day 0 for a 13-day period. Half the animals were killed at day 7 and the other half at day 13. Weights of whole body and organs/tissues (small intestine, liver, thigh muscle, and brain) were measured every day and at slaughter, respectively. In Exp 1, following the oral IGF-I administration, serum IGF-I concentration increased at hour 4 (p<0.01) and returned to the hour 0 level by hour 8, whereas glucose concentration was lowest at hour 4 and returned to the hour 0 level by hour 16. In the PBS-fed group, neither IGF-I nor glucose concentration changed during the 24-hour period. In Exp 2, weight of small intestine increased (p<0.05) in response to the oral IGF-I, whereas weights of liver and thigh muscle of the IGF-I-fed group were greater (p<0.01) and tended to be greater (p=0.06), respectively, than those of the PBS-fed only at day 13. However, brain weight and serum concentrations of IGF-I and IGF-II were not affected by oral IGF-I administration. Results suggest that although orally administered IGF-I mainly acts at the intestine, a portion of ingested IGF-I is absorbed into the general circulation to enhance the growth of selective organs/tissues in weanling mice. Copyright (C) 2006 S. Karger AG, Basel.
引用
下载
收藏
页码:199 / 204
页数:6
相关论文
共 50 条
  • [31] The cutaneous insulin-like growth factor-I system
    Werther, G
    EXPERIMENTAL DERMATOLOGY, 2003, 12 (02) : 221 - 221
  • [32] SOMATOTROPH INSULIN-LIKE GROWTH FACTOR-I SIGNALING
    PRAGER, D
    MELMED, S
    ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 1993, 692 : 102 - 112
  • [33] Insulin-like growth factor-I in liver cirrhosis
    Blomsma, MC
    deKnegt, RJ
    Dullaart, RPF
    Jansen, PLM
    JOURNAL OF HEPATOLOGY, 1997, 27 (06) : 1133 - 1138
  • [34] EXPRESSION OF INSULIN-LIKE GROWTH FACTOR-I IN SARCOMAS
    ROHOLL, PJM
    SKOTTNER, A
    PRINSEN, I
    LIPS, CJM
    DENOTTER, W
    VANUNNIK, JAM
    HISTOPATHOLOGY, 1990, 16 (05) : 455 - 460
  • [35] Therapeutic potential of insulin-like growth factor-I
    Ohkuma, T
    NIPPON NOGEIKAGAKU KAISHI-JOURNAL OF THE JAPAN SOCIETY FOR BIOSCIENCE BIOTECHNOLOGY AND AGROCHEMISTRY, 1998, 72 (02): : 189 - 192
  • [36] THE ENDOCRINE ROLE OF INSULIN-LIKE GROWTH FACTOR-I
    GLUCKMAN, PD
    DOUGLAS, RG
    AMBLER, GR
    BREIER, BH
    HODGKINSON, SC
    KOEA, JB
    SHAW, JHF
    ACTA PAEDIATRICA SCANDINAVICA, 1991, : 97 - 105
  • [37] Maternal serum insulin-like growth factor-I
    Wiwanitkit, Viroj
    JOURNAL OF THE CHINESE MEDICAL ASSOCIATION, 2014, 77 (04) : 217 - 217
  • [38] INSULIN-LIKE GROWTH FACTOR-I AND FACTOR-II
    HUMBEL, RE
    EUROPEAN JOURNAL OF BIOCHEMISTRY, 1990, 190 (03): : 445 - 462
  • [39] Insulin-like growth factor-I genotype and birthweight
    Twickler, TB
    de Sain-van der Velden, MGM
    van Doorn, J
    van Haeften, TW
    LANCET, 2002, 360 (9337): : 946 - 946
  • [40] Insulin-like growth factor-I: Clinical studies
    Vos, PE
    Koppeschaar, HPF
    de Vries, WR
    Wokke, JHJ
    DRUGS OF TODAY, 1998, 34 (01): : 79 - 90